Monthly Update Oncologic, Endocrine & Metabolic: Prevention of immune dysfunction by dehydroepiandrosterone in ageing, chronic AIDS and leukaemia patients

References

• RUDMAN D, SHETTY KR, MATTSON DE: Plasma dehy- droepiandrosterone sulfate in nursing home men. J. Amer. Geriatrics Soc. (1990) 38:421–427.
   PubMed Web of Science ®Google Scholar
• DAYNES RA, ARANEO BA, ERSHLER WB, MALONEY C, LI GZ, RYU SY: Altered regulation of 11,6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J. Immunol. (1993) 150:5219–5230.
   Google Scholar
• LORIA RM, PADGETT DA: Androstenediol regulates sys-temic resistance agoinct lethal infections in mice. Arch. Virol. (1992) 127:103–115.
   PubMed Web of Science ®Google Scholar
• REGELSON W, LORIA R, KALIMI M: Dehydroepiandros-terone (DHEA) - The "mother steriod". L Immunologic action. N.Y. Acad. Sci. (1990):553–563.
   Google Scholar
• WEI J, XU J, DAVIES JI., HEMMINGS GP: Increase in plasmaIL-6 concentration with age in healthy subjects. Life Sci. (1992) 51:1953–1956.
   Google Scholar
• DAYNES RA, DUDLEY DJ, ARANEO BA: Regulation ofmurine lymphokine production in vivo. IL Dehy-droepiandrosterone is a natural enhancer of inter-leukin 2 synthesis by helper T-cells. Eur. J. Immunol. (1990) 20:793–802.
   Google Scholar
• ROSS RD, FRENGLEY JD: Elevated C-reactive protein in older people. J. Am. Ger. Soc. (1992) 40:104–105.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, SUZUKI N, DAYNES RA, ENGLEMAN EG: Dehy-droepiandrosterone enhances 11-2 production and cy-totoxic effector function of human T-cells. Immunol. Immunopath. (1991) 61:202–211.
   PubMedGoogle Scholar
• BARRETT-CONNOR E, EDELSTEIN SL: A prospective study of dehydroepiandrosterone sulfate and cognitive func-tion in an older population: the Rancho Bernardo Study. J. Amer. Geriatrics Soc. (1994) 42:420–423.
   PubMed Web of Science ®Google Scholar
• GORDON GB, HELZLSOUER KJ, ALBERG AJ COMSTOCK GW: Serum levels of dehydroepiandrosterone and de-hydroepiandrosterone sulfate and the risk of develop-ing gastric can. Cancer Epid. Biomarkers Prevention (1993) 2:33–35.
   PubMedGoogle Scholar
• CASSON PR ANDERSEN RN, HERROD HG, STENTZ FB, STRAUGHN AB, ABRAHAM GE, BUSTER JE: Oral (itchy-droepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am. J. Obstet. Gynecol. (1993) 169:1536–1539.
   PubMedGoogle Scholar
• FAGIOLO U, COSSARIZZA A, SCALA E, FANALES-BELASIOE, ORTOLAN' C, COZZI E, MONTI D, FRANCESCHI C, PAGANELLI R: Increased cytokine production in mononuclear cells of healthy elderly people. Eur. Immunol. (1993) 23:2375–2378.
   PubMed Web of Science ®Google Scholar
• SCHWAB R, PFEFFER LM, SZABO P, GAMBLE G, SCHNURRCM, WEKSLER ME: Defective expression of high affinity IL-2 receptors on activated T-cells from aged humans. Int. Immunol. (1990) 2:239–246.
   PubMed Web of Science ®Google Scholar
• COSSARIZZA A, mONT1 D, CANTINI M, PAGANELLI R, MONTAGANI G, CADOSSI R, BERSANI F, FANCESCHI C: Extremely low frequency pulsed electromagnetic fields Increase interleukin-2 (IL-2) utilization in IL-2 receptor expression in mitogen-stimulated human lymphocytes from old subjects. FFJ3S Lett. (1989) 248:141–144.
   Google Scholar
• MEIKLE AW, DORCHUCK RW, ARANEO BA, STRINGHAM JD, EVANS TG, SPRUANCE SL, DAYNES RA: The presence of a dehyroepiandrosterone-specific receptor binding complex in murine T-cells. j Steroid Biochem. Molec. Biol. (1992) 42:293–304.
   PubMed Web of Science ®Google Scholar
• ALAK JIB, SHAHBAZIAN M, HUANG DS, WANG Y, DARBAN H, JENKINS EM, WATSON RR: Alcohol and murine ac-quired immunodeficiency syndrome suppression of resistance to Cryptosporidium parvum infection dur-ing modulation of cytokine production. Alcohol C/in. Exp. Res. (1993) 17:539–544.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN KR, MARTIN EG, HEALEY MC: Effects of dehyroepiandrosterone In inununosuppressed rats in-fected with Criptosporidiumparvum Parasitol. (1993) 79:364–370.
   Google Scholar
• RASMUSSEN KR, HEALEY MC: Dehydroepiandrosterone-induced reduction of Cryptosporidium parvum infec-tions in aged Syrian golden hamsters. J. Parasitol. (1992) 78:554–557.
   PubMed Web of Science ®Google Scholar
• VASDEV S, JOHNSON E, LONGERICH L. PRABHAKARANVM, GAULT MH: Plasma endogenous digitalis-like fac-tors in healthy individuals and in dialysis dependent and kidney transplant patients. Clin. Nephrol. (1987) 27:169–174.
   Google Scholar
• ARANEO BA, SHELBY J, LI GZ, KU W, DAYNES RA: Admini-stration of DHEA to burned mice preserves normal Immunologic competence. Arch. Surg. (1993) 128:318–325.
   PubMed Web of Science ®Google Scholar
• ARANEO BA, WOODS ML, DAYNES RA: Reversal of theimmunosenescent phenotype by dehydroepiandros-terone: Hormone treatment provides an adjuvant effect on the immunization of aged mice with recombinant hepatitis B surface antigen. 5 Infect. Dis. (1993) 167:830–840.
   PubMed Web of Science ®Google Scholar
• CHRISTEFF N, GHARAKHANIAN S, THOBIE N, ROZEN-BAUM W, NUNEZ EA: Evidence for changes in adrenal and testicular steroids during HIV infection. J. AIDS (1992) 5:841–846.
   PubMed Web of Science ®Google Scholar
• JACOBSON MA, FUSARO RE, GALMARINI M, LANG W: Decreased serum dehydroepiandrosterone is associ-ated with an increased progression of Human Immu-nodeficiency Virus infection in men with CD4 cell counts of 200-499.5 Infect. Dis. (1991) 164:864–868.
   PubMed Web of Science ®Google Scholar
• HIRANO T, KISHIMOTO T: Interleukin-6. In: Peptide Growth Factors and their Receptors. MB Spron, AB Roberts (Eds.). (1991) 1:633–665.
   Google Scholar
• WANG Y, ARDESTANI SK, HANG B, BECKHAM C, WATSONRR: Anti-interleukin-4 monoclonal antibody and inter-feron-gamma administration retards development of Immune dysfunction and cytokine dysregulation dur-ing murine AIDS. Immunology (1994) 83:384–389.
   PubMed Web of Science ®Google Scholar
• LAGNEAUX L. DELFORGE A, DORVAL C, BRON D, STRYCKMANS P: Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukaemia inhibits growth of hematopoietic precursors and interleuldn-6 produc-tion. Blood (1993) 82:2379–2385.
   PubMed Web of Science ®Google Scholar
• FOA, R., MASSAIA, M, CARDONA S, TOS AG, BIANCHI A,ATTISANO C, GUARINI A, DI CELLE PF, FIERRO MT: Pro-duction of tumor necrosis factor alpha by B-cell chronic lymphocytic leukaemia cells: A possible regulatory role of TNF in the progression of the disease. Blood (1990) 76:393–400.
   PubMed Web of Science ®Google Scholar
• ADERKA D, MAOR Y, NOVICK D, ENGELMANN H, KAHNY, LEVO Y, WALLACH D, REVEL M: Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukaemia cells that is induced by tumor necrosis factor alpha or beta. Blood (1993) 81:2076–2084.
   PubMed Web of Science ®Google Scholar
• VAN KOOTEN C, RENSINK I, AARDEN L, VAN OERS R: Effect of 11-4 and 1L-6 on the proliferation and differen-tiation of B-chronic lymphocytic leukaemia cells. Leu-kaemia (1993) 7:618–624.
   PubMed Web of Science ®Google Scholar
• REIITIE JE, HOFFBRAND AV: Interleukin-4 (IL-4) inhibitsproliferation and spontaneous cytokine release by chronic lymphocytic leukaemia cells. Leukaemia Res. (1994) 18:55–60.
   PubMed Web of Science ®Google Scholar
• BURKE F, GRIFFIN D, ELWOOD N, DAVIDS C, STAMP G,ROHATINER A, LISTER TA, BALKWILL F: The effect of cytokines on cultured mononuclear cells from patients with B-cell chronic lymphocytic leukaemia. Hem atolog. Oncolog. (1993) 11:23–33.
   PubMed Web of Science ®Google Scholar
• LA.HAT N, AGHAI E, MAROUN B, KINARTY A, QC= M, FROOM P: Increased spontaneous secretion of IL-6 from B-cells of patients with B chronic lymphatic leukaemia (B-CLL) and autoimrnunity. Clin. Exp. Immunol. (1991) 85:302–306.
   PubMed Web of Science ®Google Scholar
• FREEMAN GJ, FREEDMAN AS, RABINOWE SN SEGIL JM, HOROWITZ J, ROSEN K, WHITMAN JF, NADLER LM: Inter-leukin 6 gene expression in normal and neoplastic B-cells. J. Clin. Invest. (1989) 83:1512–1518.
   PubMed Web of Science ®Google Scholar
• BIONDI A, ROSSI V, BASSAN R, BARBUI R, BETIONI T, SIRONI S, MANTOVANI A, RAMBALDI A: Constitutive expression of the interleukin-6 gene in chronic lym-phocytic leukaemia. Blood (1989) 73:1279–1284.
   PubMed Web of Science ®Google Scholar
• RAMBALDI A, BETTONI S, ROSSI V, TINI ML, GIUDICI G, RIZZON V, BASSAN R, MANTOVANI A, BARBUI T, BIONDI A: Transcriptional and post-transcriptional regulation of IL-lbeta, IL-6 and TNF-alpha gene in chronic lympho-cytic leukaemia. Brit. J. Haematol. (1993) 83:204–211.
   PubMed Web of Science ®Google Scholar
• LINET MS, BIAS WB, DORGAN JF, MCCAFFREY LD, HUM-PHREY RL: HLA antigens in chronic lymphocytic leukae-mia. Tissue Antigens (1989) 31:71–78.
   Web of Science ®Google Scholar
• FREEDMAN AS: Immunobiology of chronic leukaemia. Hemat. Oncol. Clin. North Am. (1990) 4:405–429.
   PubMed Web of Science ®Google Scholar
• AGUILAR-SANTELIESE M. LOFIENIUS A, LJUNGH C, SVEN-SON SB, ANDERSON B, MELLSTEDT H, JONDAL M: Serum levels of helper factors (11.-1 alpha, 1L-1 beta, and 1L-6) T-cell products (sCD4 and sCD8),and 132-micro-globulin in patients with B-CLL and benign B lympho-cytosis. Leukaemia Res. (1992) 16:607–613.
   Google Scholar
• WEN T, MELLSTEDT H, JONDAL M: Presence of clonal T-cell populations in chronic B lymphocytic leukaemia and smoldering myeloma. J. Exp. Med. (1990) 171:659–666.
   PubMed Web of Science ®Google Scholar
• TOTTERMAN TH, CARLSSON M, SIMONSSON B, BENGTSSON M, NILSSON K. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood (1989) 74:786–792.
   Google Scholar
• BROSTOFF S, HOWELL T: T-cell receptors, inununoregu-lation and autohrununity. Clin. Immunol. Imtnunopatb. (1992) 62:1–7.
   PubMedGoogle Scholar
• JOSHUA DE, GIBSON J, BROWN ED: Mechanisms of the escape phase of myeloma. Blood Rev. (1994) 8:13–20.
   PubMed Web of Science ®Google Scholar
• KAWANO M, HIRANO T, MATSUDA T, TAGA T, HORU Y, IWATO K, ASAOKU H, TANG B, TANABE O, TANAKA H, KURAMOTO A, KISHIMOTO T: Autocrine generation and essential requirement of BSF-2111-6 for human multiple myelomas. Nature (1988) 332:83–85.
   PubMed Web of Science ®Google Scholar
• BURGER R, WENDLER J, ANTONI K, HELM G, KALDEN JR, GRAMATZKI M: Interleukin-6 production in B-cell neo-plasias and Castleman's disease: evidence for an addi-tional paracrine loop. Ann. Haematol. (1994) 69:25–31.
   PubMed Web of Science ®Google Scholar
• THALER J, FECHNEW F, HEROLD M, HUBER H: Inter-leukin-6 in multiple myeloma: correlation with disease activity andproliferation index. Leukaemia Lym-phoma (1994) 12:265–271.
   PubMed Web of Science ®Google Scholar
• FORTIER M, ZHANG XG, URSULE E, LESS D, JOURDAN M, BATAILLE R, KLEIN B: Cytokine gene expression in human multiple myeloma. Brit. J. Haematol. (1993) 85:514–520.
   PubMed Web of Science ®Google Scholar
• SHIMIZU, S, HIRANO T, YOSHIOKA K, SUGAI S. MATUSDAT, TAGA T, KISHIMOTO T, KONDA S: Interleukin 6 (B-cell stimulatory factor 2)-dependent growth of a Lennert's lymphoma-derived T-cell line (KT-3). Blood (1988) 72:1826–1828.
   Google Scholar
• MURAGUCHI A, HIRANO T, TANG B, MATSUDA T, HORII Y, NAKAJIMA K, KISHIMOTO T: The essential role of B-cell stimulatory factor 2 (BSF-2, EL-6) for the terminal differentiation of B-cells. J. Exp. Med. (1988) 167:332–344.
   PubMed Web of Science ®Google Scholar
• FORTIER M, ZHANG, XG, CARON E, LU ZY, BATAIIIF R, KLEIN B: Gamma-interferon in multiple myeloma: inhi-bition of interleukin-6 (11-6)-dependent myeloma cell growth and downregulation of 11-6-receptor expres-sion in vitro. Blood (1993) 81:3076–3082.
   PubMed Web of Science ®Google Scholar
• VAN OERS MH, VAN ZAANEN HC, LOKHORST HM: Inter-leukin-6, anew target for therapy in multiple myeloma? Ann. Hematol. (1993) 66:219–223.
   Web of Science ®Google Scholar
• GIRASOLE GR, JILKA L, PASSERS G, BOSWELL G, BODER D, WILLIAMS C, MANOLAGAS SC: 17 Beta-estradiol inhib-its interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mecha-nism for the antiosteoporotic effects of estrogens. J. Clin. Invest.(1992) 89:883–888.
   PubMed Web of Science ®Google Scholar
• DAYNES RA, ARANEO BA, DOWEL TA: Regulation of murine lympholthie production in vitro. III. The lym-phoid microenvironment exerts regulatory influences over T helper function. J. Exp. Med. (1990) 171:979–996.
   Google Scholar
• DAYNES RA, ARANEO BA: Contrasting effects of gluco-corticoids on the capacity of T-cells to produce the growth factor interleukin 2 and interleukin 4. Eur. J. Immunol. (1990) 19:2319–2325.
   Web of Science ®Google Scholar
• MAY M, HOLMES E, ROGERS W, POTH M: Protection from glucocorticoid-induced thymic involution by deity-droepiandrosterone. Life Sci. (1990) 46:1627–1631.
   PubMed Web of Science ®Google Scholar
• REGELSON W, KALIMI M, LORIA R: DHEA: some thoughts as to its biologic and clinical action. In: The Biologic Role of Dehydroepiandrosterone (DHEA). Kalimi M, Regelson W (Eds.). Walter de Gruyter, New York (1990):405–445.
   Google Scholar
• ROBERTS G: Dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) as neural facilitators: effects on brain tissue in culture and on memory in young and old mice. A cyclic GMP hypothesis of action of DHEA and DI1EAS in nervous system and other tissues. In: The Biologic Role of Debydroepiandrosteron (DHEA). Kalimi M, Regelson W (Eds.). Walter de Gruyter, New York (1990):13–42.
   Google Scholar
• MAJEWSKA MD, DEMIRGOREN S, SPIVA1C CE, LONDON ED: The neurosteroid DHEAS is an allosteric antagonist of the 6813A receptor. Brain Res, (1990) 526:143–146.
   PubMed Web of Science ®Google Scholar
• DEMETER J, FEHER T: Serum dehydroepiandrosterone sulphate (DHEAS) and dehydroepiandrosterone (DHEA) levels in hairy-cell lenkaecnia Eur. j Haema-tolog. (1991) 47:313–315.
   Google Scholar
• MAGEE JM, MCKENZIE S. FIIIPPA DA, ARLIN ZA, GEE TS, CLARKSON BD: Hairy cell leukaemia. Durability of re-sponse to splenectomy in 26 patients and treatment of relapse with androgens in six patients. Cancer (1985) 56:2557–2562.
   Google Scholar
• MANOHANAN A: Androgens in hairy cell leukaemia: anoverlooked treatment? Eur. J. Haematol. (1988) 42:212–214.
   Google Scholar
• BARRETT-CONNOR, E, KRITZ-SILVERSTEIN D, EDELSTEINSL: A prospective study of dehydroepiandrosterone sulfate (DHEAS) and bone mineral density in older men and women. Am. J. Epidemiology (1993) 137:201–206.
   PubMedGoogle Scholar
• Ronald Ross Watson, Department of Family and Community Medi-cine, University of Arizona, School of Medicine, Tucson, AZ 85724, USA. Supported by Wallace Genetics Foundation, Inc.
   Google Scholar